Vitamin E supplementation in preeclampsia

Gynecol Obstet Invest. 1994;37(4):246-9. doi: 10.1159/000292570.

Abstract

An oxidant/antioxidant imbalance has been suggested among the pathogenetic factors involved in preeclampsia. As vitamin E is one of the most important antioxidant body components, a nonrandomized controlled trial was undertaken in 36 preeclamptic patients in order to evaluate the effect of vitamin E supplementation (100-300 mg/day per os) on fetal and maternal outcome. Fetal mortality was similar in 14 patients treated with conventional therapy plus oral vitamin E supplementation (35%) and in 22 patients treated with conventional therapy only (36%). Furthermore, in both groups of patients proteinuria increased, and increased dosages of antihypertensive drugs were called for in order to control blood pressure. We conclude that, with these dosages and in case of an already established disease, vitamin E does not improve fetal outcome in severe preeclampsia. Furthermore, it does not show favorable effects on maternal hypertension and proteinuria.

Publication types

  • Clinical Trial

MeSH terms

  • Adult
  • Female
  • Humans
  • Hypertension / drug therapy
  • Pre-Eclampsia / drug therapy*
  • Pregnancy
  • Pregnancy Complications / drug therapy
  • Proteinuria / drug therapy
  • Vitamin E / administration & dosage
  • Vitamin E / blood
  • Vitamin E / therapeutic use*

Substances

  • Vitamin E